ArticleFrontiers in medicine2026
Thyroid cytology Bethesda category III (AUS/FLUS): surgical follow-up and histologic outcomes in a tertiary-care setting.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Indeterminate thyroid cytology, specifically category III atypia/follicular lesion of undetermined significance (AUS/FLUS), poses a diagnostic challenge and affects patient management. Methods: A retrospective review of cases reported as AUS/FLUS was conducted using the institutional thyroid fine needle aspiration (FNA) registry (2013-2022). Proportions were reported with 95% confidence intervals (CIs). Direct registry correlation and a larger all-operated sensitivity denominator were examined to capture real-world outcomes. Results: AUS/FLUS comprised 243 out of 1,872 FNAs (13.0%; 95% CI: 11.5-14.6). Of these, 186 patients (76.5%; 95% CI: 70.8-81.4) underwent surgery. Histologic follow-up identified 57 malignancies, resulting in a malignancy rate of 41.9% (95% CI: 34.0-50.3) among definitively linked cytology-histology cases ( Conclusion: In a tertiary-care setting without routine molecular testing, AUS/FLUS was prevalent and often led to surgical intervention. The malignancy reported rate was clinically significant but varied according to the denominator applied, highlighting the impact of verification and linkage effects and the necessity for clear counseling and ultrasound-informed follow-up strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.